» Articles » PMID: 15937077

Divergent Phenotypes in Gaucher Disease Implicate the Role of Modifiers

Overview
Journal J Med Genet
Specialty Genetics
Date 2005 Jun 7
PMID 15937077
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Gaucher disease is classified into neuronopathic and non-neuronopathic forms with wide phenotypic variation among patients sharing the same genotype. While homozygosity for the common L444P allele usually correlates with the neuronopathic forms, how a defined genotype leads to a phenotype remains unknown.

Methods: The genetic and epigenetic factors causing phenotypic differences were approached by a clinical association study in 32 children homozygous for the point mutation L444P. Direct sequencing and Southern blots were utilised to establish the genotype and exclude recombinant alleles. Glucocerebrosidase activity was measured in lymphoblast and fibroblast cell lines.

Results: Residual enzyme activity was highly variable and did not correlate with the observed clinical course. There was also a wide spectrum of phenotypes. Average age at diagnosis was 15 months, and slowed saccadic eye movements were the most prevalent finding. The most severe systemic complications and highest mortality occurred in splenectomised patients before the advent of enzyme replacement therapy (ERT). On ERT, as morbidity and mortality decreased, developmental and language deficits emerged as a major issue. Some trends related to ethnic background were observed.

Conclusion: The wide clinical spectrum observed in the L444P homozygotes implicates the contribution of genetic modifiers in defining the phenotype in Gaucher disease.

Citing Articles

Unifying biology of neurodegeneration in lysosomal storage diseases.

Ludlaim A, Waddington S, McKay T J Inherit Metab Dis. 2025; 48(1):e12833.

PMID: 39822020 PMC: 11739831. DOI: 10.1002/jimd.12833.


Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2.

Ging K, Frick L, Schlachetzki J, Armani A, Zhu Y, Gilormini P NPJ Parkinsons Dis. 2024; 10(1):192.

PMID: 39438499 PMC: 11496744. DOI: 10.1038/s41531-024-00819-7.


GBA-AAV mitigates sleep disruptions and motor deficits in mice with REM sleep behavior disorder.

Chen Y, Xie W, Xia D, Zhang M, Sun Y, Duan W NPJ Parkinsons Dis. 2024; 10(1):142.

PMID: 39095359 PMC: 11297138. DOI: 10.1038/s41531-024-00756-5.


Neuronopathic Gaucher disease models reveal defects in cell growth promoted by Hippo pathway activation.

Messelodi D, Strocchi S, Bertuccio S, Baden P, Indio V, Giorgi F Commun Biol. 2023; 6(1):431.

PMID: 37076591 PMC: 10115838. DOI: 10.1038/s42003-023-04813-2.


β-Glucocerebrosidase Deficiency Activates an Aberrant Lysosome-Plasma Membrane Axis Responsible for the Onset of Neurodegeneration.

Lunghi G, Carsana E, Loberto N, Cioccarelli L, Prioni S, Mauri L Cells. 2022; 11(15).

PMID: 35954187 PMC: 9367513. DOI: 10.3390/cells11152343.